Re: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
Ménard
S
S
Camerini
T
T
Mariani
L
L
Tomasic
G
G
Pilotti
S
S
Costa
A
A
De Palo
G
G
Veronesi
U
U
D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D017313:Fenretinide / Q000627:therapeutic use*; D006801:Humans; D008593:Menopause; D016609:Neoplasms, Second Primary / Q000517:prevention & control*; D016016:Proportional Hazards Models; D016032:Randomized Controlled Trials as Topic; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D012307:Risk Factors; D016896:Treatment Outcome
D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D017313:Fenretinide